TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
A total of 13 patients treated with four escalating doses of TTX-MC138No significant safety or dose limiting toxicities reportedTwo patients have so far maintained stable disease on treatment for at